

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 January 2023 (19.01.2023)



(10) International Publication Number
WO 2023/284873 A1

(51) International Patent Classification:

C12N 9/02 (2006.01) A61P 27/02 (2006.01)
C12N 15/86 (2006.01)

(21) International Application Number:

PCT/CN2022/106089

(22) International Filing Date:

15 July 2022 (15.07.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2021/106619

15 July 2021 (15.07.2021) CN

(71) Applicant: SHANGHAI VITALGEN BIOPHARMA CO., LTD. [CN/CN]; 3rd Floor, 665 Zhangjiang Road, China (Shanghai) Pilot Free Trade Zone, Shanghai 201210 (CN).

(72) Inventors: GUO, Lu; Nest.bio Labs, Unit B, Block 3, Dongsheng International Science Park, No.1 Yongtaizhuang North Road, Haidian, Beijing 100192 (CN). TAO, Yezheng; Building 2, 11 Jialilue Road, Pudong New Area, Shanghai 201210 (CN). TIAN, Shin-Shay; Building 2, 11 Jialilue Road, Pudong New Area, Shanghai 201210 (CN). QU, Bin; Building 2, 11 Jialilue Road, Pudong New Area, Shanghai 201210 (CN). LI, Wei; Beijing Institute For Stem Cell And Regenerative Medicine, Jia 3, Datun Road, Chaoyang, Beijing 100101 (CN). ZHU, Xi; Building 2, 11 Jialilue Road, Pudong New Area, Shanghai 201210 (CN). ZHAO, Xiaoping; Building 2, 11 Jialilue Road, Pudong New Area, Shanghai 201210 (CN).

(74) Agent: IPFAITH PARTNERS; Ms. Mengixn XIE 1003-1005, Telecom Industry Bldg., 65 Fuxing Rd., Haidian, Beijing 100036 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: RECOMBINANT ADENO-ASSOCIATED VIRAL VECTORS FOR TREATING BIETTI CRYSTALLINE DYSTROPHY

(57) Abstract: Provided are a recombinant adeno-associated vector comprising a codon-optimized sequence encoding CYP4V2 linked to selected gene expression regulatory sequences and its use in treating Bietti Crystalline Dystrophy (BCD).

WO 2023/284873 A1